^
    Back
    Association details:
    Biomarker:TMB-H + PD-L1 expression
    Cancer:Urothelial Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275

    Published date:
    06/12/2020
    Excerpt:
    TMB combined with PD-L1 better predicted ORR, PFS, and OS than PD-L1 alone. These results support the durable antitumor activity of nivolumab and suggest that TMB may enrich for better response in mUC.
    DOI:
    10.1158/1078-0432.CCR-19-4162